Imipridone ONC212 activates orphan G protein-coupled receptor GPR132 and integrated stress response in acute myeloid leukemia-Reference-Cited by-同舟云学术

Imipridone ONC212 activates orphan G protein-coupled receptor GPR132 and integrated stress response in acute myeloid leukemia

Published:2019-05-24 Issue:12 Volume:33 Page:2805-2816
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Nii Takenobu,Prabhu Varun V.,Ruvolo Vivian,Madhukar Neel,Zhao Ran,Mu Hong,Heese Lauren,Nishida Yuki,Kojima Kensuke,Garnett Mathew J.,McDermott Ultan,Benes Cyril H.,Charter Neil,Deacon Sean,Elemento Olivier,Allen Joshua E.,Oster Wolfgang,Stogniew Martin,Ishizawa Jo,Andreeff Michael

Funder

U.S. Department of Health & Human Services | National Institutes of Health

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/s41375-019-0491-z.pdf

Reference44 articles.

1. Allen JE, Krigsfeld G, Mayes PA, Patel L, Dicker DT, Patel AS, et al. Dual inactivation of Akt and ERK by TIC10 signals Foxo3a nuclear translocation, TRAIL gene induction, and potent antitumor effects. Sci Transl Med. 2013;5:171ra17. https://doi.org/10.1126/scitranslmed.3004828

2. Allen JE, Kline CLB, Prabhu VV, Wagner J, Ishizawa J, Madhukar N, et al. Discovery and clinical introduction of first-in-class imipridone ONC201. Oncotarget. 2016;7:74380–92. https://doi.org/10.18632/oncotarget.11814

3. Arrillaga-Romany I, Chi AS, Allen JE, Oster W, Wen PY, Batchelor TT. A phase 2 study of the first imipridone ONC201, a selective DRD2 antagonist for oncology, administered every three weeks in recurrent glioblastoma. Oncotarget. 2017;8:79298–304. https://doi.org/10.18632/oncotarget.17837